The Metabolic Syndrome and Risk of Prostate Cancer in Italy

Annals of Epidemiology

Volumn 21, Issue 11, 2011, Pages 835-841

  Pelucchi, Claudio ^a   Serraino, Diego ^b   Negri, Eva ^a   Montella, Maurizio ^c   Dellanoce, Cinzia ^d   Talamini, Renato ^b   La Vecchia, Carlo ^a,e,f  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Case Control Studies; Epidemiology; Hypercholesterolemia; Metabolic Syndrome X; Prostatic Neoplasms; Risk Factors

Indexed keywords

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CANCER RISK; DIABETES MELLITUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 80053468503     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2011.07.007     Document Type: Article

References (53)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
3. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005, 13:322-327.
4. World Health Organization (WHO) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus 1999, Vol. 99. WHO, Geneva, p. 59.
5. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
6. Cornier M.A., Dabelea D., Hernandez T.L., Lindstrom R.C., Steig A.J., Stob N.R., et al. The metabolic syndrome. Endocr Rev 2008, 29:777-822.
7. Hsing A.W., Sakoda L.C., Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007, 86:s843-s857.
8. Laukkanen J.A., Laaksonen D.E., Niskanen L., Pukkala E., Hakkarainen A., Salonen J.T. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004, 13:1646-1650.
9. Beebe-Dimmer J.L., Dunn R.L., Sarma A.V., Montie J.E., Cooney K.A. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007, 109:875-881.
10. Beebe-Dimmer J.L., Nock N.L., Neslund-Dudas C., Rundle A., Bock C.H., Tang D., et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009, 74:185-190.
11. Inoue M., Noda M., Kurahashi N., Iwasaki M., Sasazuki S., Iso H., et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009, 18:240-247.
12. Jaggers J.R., Sui X., Hooker S.P., LaMonte M.J., Matthews C.E., Hand G.A., et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009, 45:1831-1838.
13. Lund Haheim L., Wisloff T.F., Holme I., Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006, 164:769-774.
14. Martin R.M., Vatten L., Gunnell D., Romundstad P., Nilsen T.I. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009, 20:1181-1192.
15. Russo A., Autelitano M., Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer 2008, 44:293-297.
16. Tande A.J., Platz E.A., Folsom A.R. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006, 164:1094-1102.
17. Tuohimaa P., Tenkanen L., Syvala H., Lumme S., Hakulinen T., Dillner J., et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:302-307.
18. Balkau B., Charles M.A., Drivsholm T., Borch-Johnsen K., Wareham N., Yudkin J.S., et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002, 28:364-376.
19. Rumawas M.E., Meigs J.B., Dwyer J.T., McKeown N.M., Jacques P.F. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. Am J Clin Nutr 2009, 90:1608-1614.
20. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292:1440-1446.
21. Dal Maso L., Zucchetto A., La Vecchia C., Montella M., Conti E., Canzonieri V., et al. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer 2004, 90:2176-2180.
22. Decarli A., Franceschi S., Ferraroni M., Gnagnarella P., Parpinel M.T., La Vecchia C., et al. Validation of a food-frequency questionnaire to assess dietary intakes in cancer studies in Italy. Results for specific nutrients. Ann Epidemiol 1996, 6:110-118.
23. Franceschi S., Negri E., Salvini S., Decarli A., Ferraroni M., Filiberti R., et al. Reproducibility of an Italian food frequency questionnaire for cancer studies: results for specific food items. Eur J Cancer 1993, 29A:2298-2305.
24. Breslow N.E., Day N.E. Statistical Methods in Cancer Research. Vol. 1: The Analysis of Case-Control Studies 1980, IARC Science Publication 32, Geneva.
25. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
26. Bravi F., Scotti L., Bosetti C., Talamini R., Negri E., Montella M., et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol 2006, 17:1014-1017.
27. Freeman M.R., Solomon K.R. Cholesterol and prostate cancer. J Cell Biochem 2004, 91:54-69.
28. Magura L., Blanchard R., Hope B., Beal J.R., Schwartz G.G., Sahmoun A.E. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control 2008, 19:1259-1266.
29. Platz E.A., Till C., Goodman P.J., Parnes H.L., Figg W.D., Albanes D., et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009, 18:2807-2813.
30. Jacobs E.J., Rodriguez C., Bain E.B., Wang Y., Thun M.J., Calle E.E. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2213-2217.
31. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819-1825.
32. Coogan P.F., Kelly J.P., Strom B.L., Rosenberg L. Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 2010, 19:752-755.
33. Haukka J., Sankila R., Klaukka T., Lonnqvist J., Niskanen L., Tanskanen A., et al. Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010, 126:279-284.
34. Kuoppala J., Lamminpaa A., Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008, 44:2122-2132.
35. Robinson W.R., Poole C., Godley P.A. Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control 2008, 19:793-803.
36. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
37. Hernandez B.Y., Park S.Y., Wilkens L.R., Henderson B.E., Kolonel L.N. Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2009, 18:2413-2421.
38. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
39. Andersson S.O., Wolk A., Bergstrom R., Adami H.O., Engholm G., Englund A., et al. Body size and prostate cancer: a 20-year follow-up study among 135,006 Swedish construction workers. J Natl Cancer Inst 1997, 89:385-389.
40. Wright M.E., Chang S.C., Schatzkin A., Albanes D., Kipnis V., Mouw T., et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007, 109:675-684.
41. Pischon T., Boeing H., Weikert S., Allen N., Key T., Johnsen N.F., et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008, 17:3252-3261.
42. Giovannucci E. Medical history and etiology of prostate cancer. Epidemiol Rev 2001, 23:159-162.
43. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Willett W.C. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998, 9:3-9.
44. Will J.C., Vinicor F., Calle E.E. Is diabetes mellitus associated with prostate cancer incidence and survival?. Epidemiology 1999, 10:313-318.
45. Tavani A., Gallus S., Bertuzzi M., Dal Maso L., Zucchetto A., Negri E., et al. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005, 47:313-317.
46. Tavani A., Gallus S., Bosetti C., Tzonou A., Lagiou P., Negri E., et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002, 11:125-128.
47. Batty G.D., Shipley M.J., Marmot M.G., Davey Smith G. Blood pressure and site-specific cancer mortality: evidence from the original Whitehall study. Br J Cancer 2003, 89:1243-1247.
48. Buja A., Scafato E., Sergi G., Maggi S., Suhad M.A., Rausa G., et al. Alcohol consumption and metabolic syndrome in the elderly: results from the Italian longitudinal study on aging. Eur J Clin Nutr 2010, 64:297-307.
49. Kaaks R., Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001, 60:91-106.
50. Macaulay V.M. Insulin-like growth factors and cancer. Br J Cancer 1992, 65:311-320.
51. Kaaks R., Lukanova A., Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000, 3:157-172.
52. Miccoli R., Bianchi C., Odoguardi L., Penno G., Caricato F., Giovannitti M.G., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 2005, 15:250-254.
53. Bosetti C., Tavani A., Negri E., Trichopoulos D., La Vecchia C. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 2001, 54:902-906.